Free Newsletter
SPOTLIGHT: Adcock Ingram gets free license for Merck HIV remedy
South African generics maker Adcock Ingram nabbed a royalty-free license from Merck on its anti-HIV drug Stocrin (efavirenz). The South African government has been buying the brand-name drug from Merck for distribution at state-run clinics. Adcock will sell its version at a "significant discount," once it gets approval from that country's drug regulators. Merck gave a voluntary license for efavirenz to Aspen Pharmacare, Adcock's biggest competitor, two years ago; that company still awaits regulatory approval for its version of the drug. Release
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: